Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Consensus Article
  • Published:

Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education

The Pharmacogenomics Journal volume 5, pages 221–225 (2005)Cite this article

Abstract

Pharmacogenomics would be instrumental for the realization of personalized medicine in coming decades. Efforts are evident to clarify the potential bioethical, societal, and legal implications of key pharmacogenomics-based technologies projected to be soon introduced into the core practice of medicine. In sharp contrast, a lack of sufficient attention to educational aspects of pharmacogenomics, both for professionals and for society at large, is evident. In order to contribute to this discussion, a ‘Pharmacogenomics Education Forum’ was held on October 2, 2004 during the 3rd Annual Meeting of the International Society of Pharmacogenomics (ISP) at Santorini, Greece. The participants, members of the ISP Pharmacogenomics Education Forum, after deliberate discussions, proposed a document of ‘Background Statement’ and ‘Recommendations and Call for Action’ addressed to Deans of Education at Medical, Pharmaceutical, and Health Schools globally. This document has been considered by the education committee of the International Society of Pharmacogenomics and the result is presented here. We hope that this call would be listened to, and soon followed by beneficial action, ultimately leading to enhanced implementation of personalized medicine into core medical education and practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Evans WE, Relling MV . Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 464–468.

    Article  CAS  Google Scholar 

  2. Meyer UA . Pharmacogenetics—five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 669–676.

    Article  CAS  Google Scholar 

  3. Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S et al. Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 2004; 5: 779–802.

    Article  CAS  Google Scholar 

  4. Weinshilboum R, Wang L . Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004; 3: 739–748.

    Article  CAS  Google Scholar 

  5. Gurwitz D, Weizman A . Personalized psychiatry: a realistic goal. Pharmacogenomics 2004; 5: 213–217.

    Article  Google Scholar 

  6. Frueh FW, Gurwitz D . From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 2004; 5: 571–579.

    Article  Google Scholar 

  7. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–19.

    Article  Google Scholar 

  8. Dormann H, Criegee-Rieck M, Neubert A, Egger T, Geise A, Krebs S et al. Lack of awareness of community-acquired adverse drug reactions upon hospital admission: dimensions and consequences of a dilemma. Drug Saf 2003; 26: 353–362.

    Article  Google Scholar 

  9. Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, Azaz-Livshits T et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med 2004; 255: 653–663.

    Article  CAS  Google Scholar 

  10. Roche Press Release. First chip-based test for broad diagnostic use in European Union has CE mark. September 1, 2004. http://www.roche.com/med-cor-2004-09-01.

  11. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438–452.

    Article  Google Scholar 

  12. Wuttke H, Rau T, Heide R, Bergmann K, Bohm M, Weil J et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429–437.

    Article  CAS  Google Scholar 

  13. Kirchheiner J, Sasse J, Meineke I, Roots I, Brockmoller J . Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics 2003; 13: 721–728.

    Article  CAS  Google Scholar 

  14. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805–2811.

    Article  CAS  Google Scholar 

  15. Langreth R, Waldholz M . New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 1999; 4: 426–427.

    CAS  PubMed  Google Scholar 

  16. Ginsburg GS, McCarthy JJ . Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491–496.

    Article  CAS  Google Scholar 

  17. Rothstein MA, Epps PG . Ethical and legal implications of pharmacogenomics. Nat Rev Genet 2001; 2: 228–231.

    Article  CAS  Google Scholar 

  18. Moldrup C . Ethical, social and legal implications of pharmacogenomics: a critical review. Community Genet 2001; 4: 204–214.

    PubMed  Google Scholar 

  19. Lipton P . Pharmacogenetics: the ethical issues. Pharmacogenomics J 2003; 3: 14–16.

    Article  CAS  Google Scholar 

  20. Wertz DC . Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J 2003; 3: 194–196.

    Article  CAS  Google Scholar 

  21. Winkelmann BR . Pharmacogenomics, genetic testing and ethnic variability: tackling the ethical questions. Pharmacogenomics 2003; 4: 531–535.

    Article  Google Scholar 

  22. Weijer C, Miller PB . Protecting communities in pharmacogenetic and pharmacogenomic research. Pharmacogenomics J 2004; 4: 9–16.

    Article  CAS  Google Scholar 

  23. van Delden J, Bolt I, Kalis A, Derijks J, Leufkens H . Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics. Bioethics 2004; 18: 303–321.

    Article  Google Scholar 

  24. Webster A, Martin P, Lewis G, Smart A . Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004; 5: 663–669.

    Article  CAS  Google Scholar 

  25. Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H . Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 2004; 5: 676–680.

    Article  CAS  Google Scholar 

  26. Nuffield Council on Bioethics. Pharmacogenetics: ethical issues. 2003. http://www.nuffieldbioethics.org/fileLibrary/pdf/pharmacog_consultation.pdf.

  27. European Commission 2004. Ethical, legal and social aspects of genetic testing: research, development and clinical applications. European Commission Expert Group. http://europa.eu.int/comm/research/conferences/2004/genetic/pdf/report_en.pdf.

  28. Vizirianakis IS . Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. Eur J Pharm Sci 2002; 15: 243–250.

    Article  CAS  Google Scholar 

  29. Brock TP, Faulkner CM, Williams DM, Smith SR . Continuing-education programs in pharmacogenomics for pharmacists. Am J Health Syst Pharm 2002; 59: 722–725.

    PubMed  Google Scholar 

  30. McCurdy CR . Pharmacy education: from Prescott to pharmacogenomics. J Am Pharm Assoc (Wash) 2002; 42: 688–691.

    Article  Google Scholar 

  31. Sansgiry SS . The future of pharmacy education: back to which basics? Pharmacotherapy 2004; 24: 688–989.

    Article  Google Scholar 

  32. Gurwitz D, Weizman A, Rehavi M . Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci 2003; 24: 122–125.

    Article  CAS  Google Scholar 

  33. Watson RT, Suter E, Romrell LJ, Harman EM, Rooks LG, Neims AH . Moving a graveyard: how one school prepared the way for continuous curriculum renewal. Acad Med 1998; 73: 948–955.

    Article  CAS  Google Scholar 

  34. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173–192.

    Article  CAS  Google Scholar 

  35. Kohn L, Corrigan J, Donaldson M (eds). To Err is Human. Building a Safer Health System. Committee on Quality of Health Care in America. Institute of Medicine. National Academy Press: Washington, DC, 1999. http://books.nap.edu/html/to_err_is_human/.

    Google Scholar 

  36. Auxter-Parham S . Bringing pharmacogenomic assays to market. Clin Lab News 2004; 30: 1–7.

    Google Scholar 

  37. Nebert DW, Jorge-Nebert L, Vesell ES . Pharmacogenomics and ‘individualized drug therapy’: high expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3: 361–370.

    Article  Google Scholar 

  38. Pirazzoli A, Recchia G . Pharmacogenetics and pharmacogenomics: are they still promising? Pharmacol Res 2004; 49: 357–361.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Genetics & Molecular Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    D Gurwitz

  2. Department of Clinical Genetics & Human Genetics, Section Community Genetics, VU University Medical Center, Amsterdam, The Netherlands

    J E Lunshof

  3. Harokopio University of Athens, Athens, Greece

    G Dedoussis

  4. Department of Pharmacology, University of Patras Medical School, Patras, Greece

    C S Flordellis

  5. Department of Pharmacology, Clinical Pharmacology Unit, University of Cologne, Germany

    U Fuhr & J Kirchheiner

  6. David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

    J Licinio

  7. Department of Pharmacology and Psychiatry, University of Extremadura Medical School, Spain

    A Llerena

  8. Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece

    V G Manolopoulos

  9. Genetic Health Services Victoria, Murdoch Childrens Research Institute, University of Melbourne, Melbourne, Australia

    L J Sheffield

  10. Faculty of Pharmacy, INSERM U.525, University Henri Poincare Nancy 1, Nancy, France

    G Siest

  11. Laboratory of Genetics, Hospital-University Careggi, Florence, Italy

    F Torricelli

  12. University of Colorado Health Sciences, Denver, 80262, CO, USA

    V Vasiliou

  13. Clinical Chemistry/Toxicology, TDM, Pharmacogenomics, and Proteomics, Medical College of Wisconsin, Milwaukee, WC, USA

    S Wong

Authors
  1. D Gurwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J E Lunshof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Dedoussis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C S Flordellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U Fuhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Kirchheiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Licinio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Llerena
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V G Manolopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L J Sheffield
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G Siest
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F Torricelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. V Vasiliou
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to D Gurwitz or J E Lunshof.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gurwitz, D., Lunshof, J., Dedoussis, G. et al. Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. Pharmacogenomics J 5, 221–225 (2005). https://doi.org/10.1038/sj.tpj.6500312

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500312

Keywords

This article is cited by

Search

Advanced search

Quick links